HC Wainwright Cuts Hookipa Pharma (NASDAQ:HOOK) Price Target to $5.00

Hookipa Pharma (NASDAQ:HOOK) had its target price decreased by HC Wainwright from $6.50 to $5.00 in a research note published on Friday morning, Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Hookipa Pharma’s Q1 2025 earnings at ($0.17) EPS, Q2 2025 earnings at ($0.18) EPS, Q3 2025 earnings at ($0.19) EPS and Q4 2025 earnings at ($0.19) EPS.

Separately, Royal Bank of Canada reiterated an outperform rating and set a $5.00 price target on shares of Hookipa Pharma in a research note on Monday, March 25th.

Hookipa Pharma Price Performance

NASDAQ:HOOK opened at $0.89 on Friday. Hookipa Pharma has a 12 month low of $0.41 and a 12 month high of $2.05. The company’s 50 day moving average is $0.75 and its 200-day moving average is $0.66.

Hookipa Pharma (NASDAQ:HOOK) last announced its earnings results on Friday, March 22nd. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.09. Hookipa Pharma had a negative net margin of 405.28% and a negative return on equity of 72.30%. The business had revenue of $7.41 million for the quarter, compared to analyst estimates of $3.60 million. Sell-side analysts forecast that Hookipa Pharma will post -0.51 EPS for the current year.

About Hookipa Pharma

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.